BG103852A - Cog-2 selective carprophene for the treatment of pains and inflammations in dogs - Google Patents

Cog-2 selective carprophene for the treatment of pains and inflammations in dogs

Info

Publication number
BG103852A
BG103852A BG103852A BG10385299A BG103852A BG 103852 A BG103852 A BG 103852A BG 103852 A BG103852 A BG 103852A BG 10385299 A BG10385299 A BG 10385299A BG 103852 A BG103852 A BG 103852A
Authority
BG
Bulgaria
Prior art keywords
cog
activity
acids
inhibition
dogs
Prior art date
Application number
BG103852A
Other languages
Bulgarian (bg)
Inventor
Kristin LUNDI
Anthony RICKETTS
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG103852A publication Critical patent/BG103852A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to the treatment or prevention of inflammatory processes and diseases in dogs related to the activity of induced cyclooxygenase-2 (COG-2). Any unwanted side effects caused by the simultaneous inhibition of the activity of the composite cyclooxygenase-1 (COG-1) are either reduced or removed by means of selective inhibition of the COG-2 activity in relation to COG-1 activity. The ratio between selectivity or COG-2:COG-1 activity of inhibition is at least 3:1 based on ex vivo levels of inhibition measured in the entire blood. The inhibitor is selected from the group of antiphlogistic compounds consisting in their basis of derivatives of the salicylic acid, of paraaminophenol, indole and indene acetic acids, heteroarylacetic acids, arylpropionic acids, anthranil acids, enol acids and alkanons. The inhibitor in particular consists of (+)(S)-enantiomer of 6-chlor-alpha -methyl-9H-carbazole-2-acetic acid. 14 claims
BG103852A 1997-05-05 1999-11-03 Cog-2 selective carprophene for the treatment of pains and inflammations in dogs BG103852A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4563597P 1997-05-05 1997-05-05
PCT/IB1998/000662 WO1998050033A1 (en) 1997-05-05 1998-05-01 Cox-2 selective carprofen for treating pain and inflammation in dogs

Publications (1)

Publication Number Publication Date
BG103852A true BG103852A (en) 2000-06-30

Family

ID=21939053

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103852A BG103852A (en) 1997-05-05 1999-11-03 Cog-2 selective carprophene for the treatment of pains and inflammations in dogs

Country Status (32)

Country Link
EP (1) EP0988034A1 (en)
JP (1) JP2000513020A (en)
KR (2) KR20040004406A (en)
CN (1) CN1255059A (en)
AP (1) AP9801234A0 (en)
AR (2) AR011726A1 (en)
AU (1) AU6932198A (en)
BG (1) BG103852A (en)
BR (1) BR9808720A (en)
CA (1) CA2288759A1 (en)
DZ (1) DZ2479A1 (en)
EA (1) EA003696B1 (en)
GT (1) GT199800063A (en)
HR (1) HRP980244A2 (en)
HU (1) HUP0001286A3 (en)
ID (1) ID21311A (en)
IL (1) IL132570A0 (en)
IS (1) IS5220A (en)
MA (1) MA26491A1 (en)
NO (1) NO995389L (en)
NZ (1) NZ500183A (en)
OA (1) OA11213A (en)
PA (1) PA8450601A1 (en)
PE (1) PE72599A1 (en)
PL (1) PL337003A1 (en)
SK (1) SK148199A3 (en)
TN (1) TNSN98059A1 (en)
TW (1) TW590773B (en)
UY (1) UY24989A1 (en)
WO (1) WO1998050033A1 (en)
YU (1) YU55899A (en)
ZA (1) ZA983722B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245797B1 (en) 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
US6506785B2 (en) 1998-05-22 2003-01-14 Pfizer, Inc. Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives
AU2003204888B2 (en) * 1998-05-22 2005-07-28 Pfizer Products Inc. Treating or Preventing the Early Stages of Degeneration of Articular Cartilage or Subchondral Bone in Mammals Using Carprofen and Derivatives
CA2347365A1 (en) * 1998-10-23 2000-05-04 Merck Frosst Canada & Co. Combination product comprising an e-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use
EP1637137A3 (en) * 1999-03-10 2006-07-05 G.D. Searle LLC Method and composition for administering a cyclooxygenase-2 inhibitor to animals
AU1592901A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
JP2004521856A (en) * 2000-05-15 2004-07-22 メルク フロスト カナダ アンド カンパニー Combination therapy using a COX-2 selective inhibitor and a thromboxane inhibitor and compositions therefor
AU6837701A (en) 2000-06-13 2001-12-24 American Home Prod Analgesic and anti-inflammatory compositions containing cox-2 inhibitors
DE10032132A1 (en) * 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermal therapeutic system containing non-steroidal anti-inflammatory drugs with selective COX-2 inhibition
US20020106707A1 (en) 2000-08-07 2002-08-08 Marnett Lawrence J. Compositions and methods for detecting and quantifying COX-2 activity and anandamide metabolites
US20040209959A1 (en) * 2001-07-16 2004-10-21 Edward Hogestatt Congeners of acetaminophen and related compounds as substrates for fatty acid conjugation and their use in treatment of pain, fever and inflammation
PT1534305E (en) 2003-05-07 2007-02-28 Osteologix As Treating cartilage / bone conditions with water-soluble strontium salts
WO2005009436A1 (en) * 2003-07-31 2005-02-03 Pharmacia & Upjohn Company Llc Dispersible formulation of an anti-inflammatory agent
EP1940380A2 (en) * 2005-05-20 2008-07-09 Pfizer Limited Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-2 delta-ligands
US8535713B2 (en) 2007-04-04 2013-09-17 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
US8951570B2 (en) 2007-04-26 2015-02-10 Sigmoid Pharma Limited Manufacture of multiple minicapsules
JP5640079B2 (en) 2009-05-18 2014-12-10 シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ Oil droplet-containing composition
BR112012002963A2 (en) 2009-08-12 2017-10-24 Sigmoid Pharma Ltd immunomodulatory compositions comprising a polymer matrix and an oil phase
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CA2941008C (en) 2014-03-06 2022-07-26 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
EP3215127B1 (en) 2014-11-07 2020-10-28 Sublimity Therapeutics Limited Compositions comprising cyclosporin
BR112017014750A2 (en) * 2015-01-09 2018-06-19 Jaguar Animal Health methods for treating diarrhea in pets
CN115335046A (en) * 2020-03-25 2022-11-11 思研（Sri）国际顾问与咨询公司 Lipoxygenase inhibitors
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
KR102404883B1 (en) 2020-11-30 2022-06-07 (주)이노보테라퓨틱스 Pharmaceutical composition for preventing or treating keloid or hypertrophic scar comprising Benzbromarone

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896145A (en) * 1972-07-24 1975-07-22 Hoffmann La Roche Carbazoles
CA1319886C (en) * 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions

Also Published As

Publication number Publication date
WO1998050033A1 (en) 1998-11-12
HUP0001286A3 (en) 2000-12-28
AP9801234A0 (en) 1999-11-04
HUP0001286A2 (en) 2000-11-28
KR20010012300A (en) 2001-02-15
DZ2479A1 (en) 2003-02-01
PA8450601A1 (en) 2000-05-24
MA26491A1 (en) 2004-12-20
JP2000513020A (en) 2000-10-03
EA003696B1 (en) 2003-08-28
BR9808720A (en) 2000-07-11
EP0988034A1 (en) 2000-03-29
HRP980244A2 (en) 1999-02-28
TNSN98059A1 (en) 2005-03-15
PE72599A1 (en) 1999-08-12
SK148199A3 (en) 2001-09-11
CN1255059A (en) 2000-05-31
AU6932198A (en) 1998-11-27
AR011726A1 (en) 2000-08-30
ZA983722B (en) 1999-11-04
ID21311A (en) 1999-05-20
PL337003A1 (en) 2000-07-31
GT199800063A (en) 1999-10-26
NO995389L (en) 2000-01-04
NZ500183A (en) 2002-04-26
OA11213A (en) 2003-07-14
EA199900895A1 (en) 2000-06-26
NO995389D0 (en) 1999-11-04
CA2288759A1 (en) 1998-11-12
IS5220A (en) 1999-10-19
AR039628A2 (en) 2005-03-02
YU55899A (en) 2003-08-29
KR20040004406A (en) 2004-01-13
TW590773B (en) 2004-06-11
UY24989A1 (en) 2001-10-25
IL132570A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
BG103852A (en) Cog-2 selective carprophene for the treatment of pains and inflammations in dogs
DE69805846T2 (en) USE OF 3-BENZOYLPHENYL ACETIC ACIDS, THEIR ESTERS OR AMIDES FOR THE TREATMENT OF GLC1A GLAUCOMA
DE59711321D1 (en) NEW SUBSTITUTED PYRAZOLE DERIVATIVES FOR THE TREATMENT OF HEART CIRCULAR DISEASES
CA2241981A1 (en) Method of inhibiting photoaging of skin
ATE407573T1 (en) USE OF TOPICALLY ADMINISTERED LYSINE TO IMPROVE VASCULAR FUNCTION
DE69634951D1 (en) TOPICAL USE OF BETULINIC ACID FOR THE TREATMENT OF POOR MELANOMA
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
CA2168963A1 (en) Drug for prevention and therapy of diseases caused by fibrinoid formation or thrombus formation in the lung and model animals of the diseases
DE69526183T2 (en) TOPICAL COMPOSITIONS CONTAINING 3-BENZOYLPHENYL ACETIC ACID DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC INFLAMMATORY DISEASES
WO1994020062A3 (en) Balanoids as protein kinase c inhibitors
ATE321548T1 (en) USE OF STATIN TO TREAT SKIN DISEASES
DE69613693T2 (en) 2-HETEROARYLALKENYL DERIVATIVES OF CYCLOPENTANO-HEPTANE (HEPTAEN) ACID AS A THERAPEUTIC AGENT FOR TREATING THE INCREASED EYE PRESSURE
ES2162051T3 (en) DERMATOLOGICAL PREPARATION TO TREAT ACTINIC KERATOSIS.
DE69611452T2 (en) BENZOTHIOPHENE DERIVATIVES
ATE198751T1 (en) AZODERIVATES OF 5-AMINOSALICYLIC ACID FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
NO20006506D0 (en) Use of Valproic Acid Analog for the Treatment and Prevention of Migraine and Affective Diseases
FR2755011B1 (en) USE OF INHIBITORS OF RETINOIC ACID ACTIVITY TO TREAT SENSITIVE SKIN AND / OR ACUTE DAMAGE INDUCED BY U.V. RADIATION
ZA978400B (en) Use of inhibitors of the activity of retinoic acid to promote healing.
DE69518073T2 (en) Pyrazole carboxylic acid derivatives as agents for combating plant diseases
CA2362888A1 (en) Use of r-aryl propionic acids for producing medicaments to treat diseases in humans and animals, whereby said diseases can be therapeutically influenced by inhibiting the activation of nf-kb
DE69735417D1 (en) 2,5-DIHYDROXYBENZYLSULFON DERIVATIVES FOR THE TREATMENT OF SEXUAL DISORDERS
MX26142A (en) DERIVATIVES OF BENZOIC ACID TO TREAT DISEASES RELATED TO LEUCOTRENE.
ATE238796T1 (en) NUCLEOSIDE DERIVATIVES IN COMBINATION PREPARATIONS FOR THE TREATMENT OF HSV DISEASES
DE69739190D1 (en) MEDICAMENT FOR THE TREATMENT OF OCULAR CRUSH DISEASES
HUP9902417A2 (en) Acylated enol derivatives of alfa-ketoesters and alfa-ketoamides